Following a challenge brought by Novo Nordisk Inc., BBB National Programs’ National Advertising Division recommended Willow ...

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

Shares of Danish pharmaceutical giant Novo Nordisk fell sharply after its Alzheimer's drug failed to slow progression of the ...

The manufacturers of Ozempic and Mounjaro are creating oral weight loss medications that could change treatment methods.

A once-a-day pill could offer “more access” to weight loss medication, experts have said after a new study confirmed the tablet can help people shed up to a tenth of their body weight. Researchers ...

Real-world data show that the GLP-1 receptor agonists semaglutide and tirzepatide not only manage blood sugar and weight but also mirror their heart-protective effects from clinical trials in everyday ...

https://www.thehindubusinessline.com/companies/zydus-torrent-ready-semaglutide-launches-in-india-and-brazil/article70261780.ece Copy Zydus Lifesciences Ltd and ...

A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular protection—reducing heart attack, stroke, and death in adults with type 2 ...

ZDNET experts put every product through rigorous testing and research to curate the best options for you. If you buy through our links, we may earn a commission. Learn Our Process 'ZDNET Recommends': ...